Takeda Pharmaceutical Company Limited (TAK)Healthcare | Drug Manufacturers - Specialty & Generic | Tokyo, Japan | NYSE
17.83 USD
+0.05
(0.253%)
⇧
(April 17, 2026, 3:48 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★★★☆ | Dividends: ★★★★☆ |
Hot Take | April 11, 2026, 3:01 p.m. EDT
Takeda Pharmaceutical (TAK) presents a mixed opportunity. The stock has shown some volatility in the short term, with a recent dip below the 52-week low. However, the dividend yield is attractive, and the company has a solid financial foundation. The options activity suggests a cautious outlook with both bullish and bearish positions. For short-term traders, there may be a buying opportunity if the stock rebounds, while long-term investors might consider holding for potential growth. The dividend yield and stable payout ratio make it a good option for income-focused investors. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.066471 |
| AutoARIMA | 0.069837 |
| AutoETS | 0.070763 |
| MSTL | 0.072402 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 60% |
| H-stat | 1.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.016 |
| Excess Kurtosis | 1.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2025-09-29 |
| Last Dividend Date | 2025-03-30 |
| Debt to Equity Ratio | 70.93 |
| Revenue per Share | 1417.2314 |
| Market Cap | 56,312,614,912 |
| Trailing P/E | 81.02 |
| Forward P/E | 33.63 |
| Beta | 0.13 |
| Profit Margins | 2.53% |
| Website | https://www.takeda.com |
As of April 11, 2026, 3:01 p.m. EDT: Options activity shows a mix of call and put positions. Calls are more active with higher open interest (OI) on the 17.5 strike, suggesting potential bullish sentiment. However, puts are also present, particularly on the 15.0 strike, indicating some bearish sentiment. The IV for calls is higher, which may indicate increased volatility expectations. Overall, there is a balanced view with both bullish and bearish signals.
| Date | Dividend | Yield % |
|---|---|---|
| 2025-03-31 | 0.339 | 2.279758 |
| 2024-09-30 | 0.326 | 2.345375 |
| 2024-03-27 | 0.292 | 2.153490 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.19089079 |
| Address1 | 1-1, Nihonbashi-Honcho 2-chome |
| Address2 | Chuo-ku |
| All Time High | 31.29 |
| All Time Low | 12.28 |
| Ask | 17.84 |
| Ask Size | 11,500 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 3,082,200 |
| Average Daily Volume3 Month | 3,104,177 |
| Average Volume | 3,104,177 |
| Average Volume10Days | 3,082,200 |
| Beta | 0.126 |
| Bid | 17.83 |
| Bid Size | 9,100 |
| Book Value | 30.511847 |
| City | Tokyo |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Japan |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 17.825 |
| Current Ratio | 1.194 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 17.98 |
| Day Low | 17.79 |
| Debt To Equity | 70.93 |
| Display Name | Takeda Pharmaceutical Company |
| Dividend Date | 1,765,411,200 |
| Dividend Rate | 0.66 |
| Dividend Yield | 3.72 |
| Earnings Call Timestamp End | 1,746,698,400 |
| Earnings Call Timestamp Start | 1,746,698,400 |
| Earnings Growth | 3.302 |
| Earnings Quarterly Growth | 3.357 |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,778,675,400 |
| Earnings Timestamp Start | 1,778,675,400 |
| Ebitda | 1,273,957,056,512 |
| Ebitda Margins | 0.28535 |
| Enterprise To Ebitda | 3.765 |
| Enterprise To Revenue | 1.074 |
| Enterprise Value | 4,796,260,024,320 |
| Eps Forward | 0.53 |
| Eps Trailing Twelve Months | 0.22 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,759,190,400 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 81 3 3278-2000 |
| Fifty Day Average | 18.204 |
| Fifty Day Average Change | -0.3789997 |
| Fifty Day Average Change Percent | -0.020819584 |
| Fifty Two Week Change Percent | 19.089079 |
| Fifty Two Week High | 18.9 |
| Fifty Two Week High Change | -1.0749989 |
| Fifty Two Week High Change Percent | -0.056878246 |
| Fifty Two Week Low | 12.99 |
| Fifty Two Week Low Change | 4.835001 |
| Fifty Two Week Low Change Percent | 0.3722095 |
| Fifty Two Week Range | 12.99 - 18.9 |
| Financial Currency | JPY |
| First Trade Date Milliseconds | 1,262,701,800,000 |
| Five Year Avg Dividend Yield | 4.61 |
| Float Shares | 1,577,937,835 |
| Forward Eps | 0.53 |
| Forward P E | 33.63208 |
| Free Cashflow | 536,711,266,304 |
| Full Exchange Name | NYSE |
| Full Time Employees | 47,455 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.65525 |
| Gross Profits | 2,925,414,055,936 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00017000001 |
| Held Percent Institutions | 0.02724 |
| Implied Shares Outstanding | 3,159,192,822 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://www.takeda.com/investor-information/ |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,743,379,200 |
| Last Dividend Value | 0.339 |
| Last Fiscal Year End | 1,743,379,200 |
| Long Business Summary | Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan. |
| Long Name | Takeda Pharmaceutical Company Limited |
| Market | us_market |
| Market Cap | 56,312,614,912 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_874540 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 112,925,999,104 |
| Next Fiscal Year End | 1,774,915,200 |
| Non Diluted Market Cap | 56,152,024,181 |
| Number Of Analyst Opinions | 3 |
| Open | 17.79 |
| Operating Cashflow | 1,189,061,984,256 |
| Operating Margins | 0.108459994 |
| Payout Ratio | 2.7905 |
| Peg Ratio | 0.3854 |
| Phone | 81 3 3278-2111 |
| Previous Close | 17.78 |
| Price Hint | 2 |
| Price To Book | 0.58419937 |
| Price To Sales Trailing12 Months | 0.0126132 |
| Profit Margins | 0.025290001 |
| Quick Ratio | 0.541 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.045000076 |
| Regular Market Change Percent | 0.25309378 |
| Regular Market Day High | 17.98 |
| Regular Market Day Low | 17.79 |
| Regular Market Day Range | 17.79 - 17.98 |
| Regular Market Open | 17.79 |
| Regular Market Previous Close | 17.78 |
| Regular Market Price | 17.825 |
| Regular Market Time | 1,776,455,327 |
| Regular Market Volume | 2,120,291 |
| Return On Assets | 0.02471 |
| Return On Equity | 0.01503 |
| Revenue Growth | 0.042 |
| Revenue Per Share | 1,417.2314 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,159,192,822 |
| Shares Percent Shares Out | 0.0022 |
| Shares Short | 6,834,466 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 6,976,158 |
| Short Name | Takeda Pharmaceutical Company L |
| Short Percent Of Float | 0.0022 |
| Short Ratio | 2.55 |
| Source Interval | 15 |
| Symbol | TAK |
| Target High Price | 22.011932 |
| Target Low Price | 18.759302 |
| Target Mean Price | 20.643085 |
| Target Median Price | 21.158018 |
| Total Cash | 654,937,030,656 |
| Total Cash Per Share | 414.623 |
| Total Debt | 5,421,965,246,464 |
| Total Revenue | 4,464,578,134,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 198.0 |
| Trailing Annual Dividend Yield | 11.136107 |
| Trailing Eps | 0.22 |
| Trailing P E | 81.02273 |
| Trailing Peg Ratio | 0.3854 |
| Triggerable | 1 |
| Two Hundred Day Average | 15.6828 |
| Two Hundred Day Average Change | 2.1422005 |
| Two Hundred Day Average Change Percent | 0.13659553 |
| Type Disp | Equity |
| Volume | 2,120,291 |
| Website | https://www.takeda.com |
| Zip | 103-8668 |